Expert Insights
Progress in Adult Acute Lymphoblastic Leukemia: More Treatment Options, Improved Outcomes
Release Date: February 26, 2020
Expiration Date: February 25, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
Survival and cure rates for patients with acute lymphoblastic leukemia (ALL) have improved markedly due to a number of factors: an enhanced understanding of molecular genetics and disease pathogenesis, the implementation of risk-adapted therapeutic strategies, the use of allogeneic hematopoietic stem cell transplantation, the development of targeted agents, and the incorporation of regimens typically used for children that may benefit adults. In this expert review, Daniel DeAngelo, MD, PhD discusses disease pathophysiology and epidemiology, as well as how to determine patients’ risk categories and identify initial therapy accordingly. He also provides practical advice on how to mitigate treatment-related adverse events and better educate patients about their disease and treatments to ensure better adherence and outcomes.
Format
eNewsletter with interactive benchmarking and audio commentary
Learning Objectives
After completing this activity, participants should be better able to:
- Identify the symptoms, classification, and stages of initial treatment for ALL
- Evaluate novel agents for ALL, including where they fit in the treatment paradigm and their potential benefits and risks
- Implement strategies to more effectively educate patients on the treatment of ALL, including possible adverse events of novel treatments and how to address them
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Daniel J. DeAngelo, MD, PhD
- Chief, Division of Leukemia
- Dana-Farber Cancer Institute
- Professor of Medicine
- Harvard Medical School
- Boston, Massachusetts
Details
Joint Accreditation Statement
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
Nurse planner: Natasha L. Johnson, MSN, APRN, AOCNP, Moffitt Cancer Center, Tampa, Florida
AAPA Credit Designation
Continuing Education Alliance has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until February 25, 2021. PAs should claim only credit commensurate with the extent of their participation.
PA planner: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Servier Pharmaceuticals LLC.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr DeAngelo: consultant: Amgen, Autolus Therapeutics, Celgene, Incyte, Jazz Pharmaceuticals, Pfizer, Shire, Takeda; consultant/grant support: Blueprint Medicines, Novartis; grant support: AbbVie, Glycomimetics.
Ms Johnson has no relevant financial relationships to disclose.
Ms Williams: consultant: AstraZeneca.
None of the members of the Planning Committee or CE Alliance staff have any relevant relationships to disclose, except Ms Williams as noted above.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hour.
Release date: February 26, 2020
Expiration date: February 25, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97719SVPCE